Sarepta Therapeutics annual operating cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Operating Cash Flow Growth & History (SRPT)
Sarepta Therapeutics's operating cash flow was −$205.5M for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$205.5M | $308,000 | — |
| 2024 | 2024-12-31 | −$205.8M | $295.2M | — |
| 2023 | 2023-12-31 | −$501.0M | −$175.6M | — |
| 2022 | 2022-12-31 | −$325.3M | $117.8M | — |
| 2021 | 2021-12-31 | −$443.2M | −$550.6M | — |
| 2020 | 2020-12-31 | $107.5M | $563.9M | — |
| 2019 | 2019-12-31 | −$456.5M | −$67.8M | — |
| 2018 | 2018-12-31 | −$388.7M | −$156.7M | — |
| 2017 | 2017-12-31 | −$232.0M | $13.8M | — |
| 2016 | 2016-12-31 | −$245.8M | −$96.4M | — |
| 2015 | 2015-12-31 | −$149.5M | −$20.9M | — |
| 2014 | 2014-12-31 | −$128.5M | −$63.8M | — |
| 2013 | 2013-12-31 | −$64.7M | −$35.0M | — |
| 2012 | 2012-12-31 | −$29.7M | −$6.0M | — |
| 2011 | 2011-12-31 | −$23.7M | −$8.5M | — |
| 2010 | 2010-12-31 | −$15.2M | −$6.4M | — |
| 2009 | 2009-12-31 | −$8.8M | — | — |
Sarepta Therapeutics quarterly operating cash flow
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $197.1M | −$64.3M | −24.59% |
| Q1 2026 | 2026-03-31 | −$202.7M | $380.8M | — |
| Q4 2025 | 2025-12-31 | $131.2M | $39.2M | +42.54% |
| Q3 2025 | 2025-09-30 | −$14.6M | $56.1M | — |
| Q2 2025 | 2025-06-30 | $261.3M | $246.4M | +1649.01% |
| Q1 2025 | 2025-03-31 | −$583.4M | −$341.4M | — |
| Q4 2024 | 2024-12-31 | $92.0M | $146.7M | — |
| Q3 2024 | 2024-09-30 | −$70.7M | $44.0M | — |
| Q2 2024 | 2024-06-30 | $14.9M | $137.2M | — |
| Q1 2024 | 2024-03-31 | −$242.1M | −$32.7M | — |
| Q4 2023 | 2023-12-31 | −$54.7M | $37.7M | — |
| Q3 2023 | 2023-09-30 | −$114.7M | −$49.7M | — |
| Q2 2023 | 2023-06-30 | −$122.2M | −$55.4M | — |
| Q1 2023 | 2023-03-31 | −$209.4M | −$108.2M | — |
| Q4 2022 | 2022-12-31 | −$92.4M | −$63.1M | — |
| Q3 2022 | 2022-09-30 | −$65.0M | $59.4M | — |
| Q2 2022 | 2022-06-30 | −$66.8M | $42.3M | — |
| Q1 2022 | 2022-03-31 | −$101.2M | $79.2M | — |
| Q4 2021 | 2021-12-31 | −$29.3M | $145.2M | — |
| Q3 2021 | 2021-09-30 | −$124.3M | $113.9M | — |
| Q2 2021 | 2021-06-30 | −$109.1M | −$1.5M | — |
| Q1 2021 | 2021-03-31 | −$180.4M | −$808.2M | — |
| Q4 2020 | 2020-12-31 | −$174.5M | −$10.7M | — |
| Q3 2020 | 2020-09-30 | −$238.2M | −$170.8M | — |
| Q2 2020 | 2020-06-30 | −$107.6M | −$28.6M | — |
| Q1 2020 | 2020-03-31 | $627.8M | $774.0M | — |
| Q4 2019 | 2019-12-31 | −$163.8M | −$41.4M | — |
| Q3 2019 | 2019-09-30 | −$67.4M | $45.9M | — |
| Q2 2019 | 2019-06-30 | −$79.0M | $38.3M | — |
| Q1 2019 | 2019-03-31 | −$146.2M | −$110.6M | — |
| Q4 2018 | 2018-12-31 | −$122.4M | −$91.4M | — |
| Q3 2018 | 2018-09-30 | −$113.3M | −$55.4M | — |
| Q2 2018 | 2018-06-30 | −$117.3M | −$32.1M | — |
| Q1 2018 | 2018-03-31 | −$35.7M | $22.2M | — |
| Q4 2017 | 2017-12-31 | −$31.1M | $50.2M | — |
| Q3 2017 | 2017-09-30 | −$57.9M | $2.7M | — |
| Q2 2017 | 2017-06-30 | −$85.1M | −$41.9M | — |
| Q1 2017 | 2017-03-31 | −$57.9M | $2.8M | — |
| Q4 2016 | 2016-12-31 | −$81.2M | −$50.0M | — |
| Q3 2016 | 2016-09-30 | −$60.6M | −$14.3M | — |
| Q2 2016 | 2016-06-30 | −$43.3M | −$14.8M | — |
| Q1 2016 | 2016-03-31 | −$60.7M | −$17.3M | — |
| Q4 2015 | 2015-12-31 | −$31.3M | −$5.8M | — |
| Q3 2015 | 2015-09-30 | −$46.3M | −$11.0M | — |
| Q2 2015 | 2015-06-30 | −$28.5M | $11.0M | — |
| Q1 2015 | 2015-03-31 | −$43.3M | −$15.1M | — |
| Q4 2014 | 2014-12-31 | −$25.4M | −$7.6M | — |
| Q3 2014 | 2014-09-30 | −$35.3M | −$15.4M | — |
| Q2 2014 | 2014-06-30 | −$39.5M | −$27.5M | — |
| Q1 2014 | 2014-03-31 | −$28.3M | −$13.3M | — |
| Q4 2013 | 2013-12-31 | −$17.8M | −$10.7M | — |
| Q3 2013 | 2013-09-30 | −$19.9M | −$12.1M | — |
| Q2 2013 | 2013-06-30 | −$12.0M | −$6.3M | — |
| Q1 2013 | 2013-03-31 | −$15.0M | −$5.9M | — |
| Q4 2012 | 2012-12-31 | −$7.2M | −$1.5M | — |
| Q3 2012 | 2012-09-30 | −$7.8M | −$282,000 | — |
| Q2 2012 | 2012-06-30 | −$5.7M | −$5.2M | — |
| Q1 2012 | 2012-03-31 | −$9.0M | $1.0M | — |
| Q4 2011 | 2011-12-31 | −$5.6M | — | — |
| Q3 2011 | 2011-09-30 | −$7.5M | −$4.8M | — |
| Q2 2011 | 2011-06-30 | −$442,000 | — | — |
| Q1 2011 | 2011-03-31 | −$10.1M | — | — |
| Q3 2010 | 2010-09-30 | −$2.8M | — | — |
Sarepta Therapeutics operating cash flow trends
Over the last five fiscal years, Sarepta Therapeutics's operating cash flow decreased from $107.5M to −$205.5M, a change of −$312.9M. The latest reported quarter, Q2 2026, shows $197.1M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...